Manic Disorder Clinical Trial
Official title:
An Observational Post-Authorisation Safety Specialist Cohort Monitoring Study (SCEM) to Monitor the Safety and Utilisation of Asenapine (Sycrest) in the Mental Health Trust Setting in England
The purpose of this observational study is to evaluate the use and short term safety of Asenapine (Sycrest) in real-life usage in the Mental Health Trust Setting in the United Kingdom(UK) National Health Service (NHS). The study is to be carried out independently by the Drug Safety Research Unit (DSRU) in Southampton, although it is funded by Merck, the manufacturer of Sycrest.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00250367 -
A Study of the Effectiveness and Safety of Risperidone Versus Placebo as add-on Therapy to Mood Stabilizers, in the Treatment of Manic Episodes Associated With Bipolar Disorder.
|
Phase 3 | |
| Completed |
NCT00521365 -
Effectiveness of Quetiapine XR on the Control of Symptoms of Manic Phase of Bipolar Disorder.
|
Phase 4 | |
| Completed |
NCT00253162 -
A Study of the Effectiveness and Safety of Risperidone Compared With Placebo in the Treatment of Manic Episodes Associated With Bipolar I Disorder, and the Maintenance of Anti-manic Effectiveness of Risperidone Compared With Haloperidol
|
Phase 3 | |
| Completed |
NCT00422123 -
Phase 3 /Seroquel SR Acute Mania Monotherapy - US
|
Phase 3 | |
| Completed |
NCT00431184 -
Effects of Pentazocine Versus Lorazepam on Manic Symptoms
|
Phase 2 | |
| Completed |
NCT00253149 -
A Study of the Effectiveness and Safety of Risperidone as add-on Therapy to Mood Stabilizers in the Treatment of Manic Episodes Associated With Bipolar Disorder
|
Phase 3 |